Cycle, Catalent to Develop Formulations Targeting Rare Disorders


Agreement covers four products that will leverage Catalent’s Zydis ODT technologies.

Cycle Pharmaceuticals Ltd. has signed an agreement with Catalent to develop innovative formulations targeting rare metabolic and neurological disorders. The agreement covers four products and each will use Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. 

Zydis technology is recognized as one of the best performing ODTs and offers advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience. The Zydis Ultra platform is the company’s next-gen ODT technology and allows for increased drug load and better taste masking to be incorporated into its proven Zydis ODT dosage form.

Antonio Benedetti, chief executive officer of Cycle said, “Cycle’s core area of expertise is to improve rare disease medicines in order to make life easier for patients of all ages.  These drug products will benefit patients with a broad range of unmet needs.  Zydis technology has consistently proven its effectiveness in overcoming challenges faced by patients, such as swallowing difficulties and large pill burdens.  Working in partnership with Catalent to apply the Zydis technology to Cycle’s product pipeline will be life-changing for both patients and their caregivers.”
Jonathan Arnold, president of Catalent’s Oral Drug Delivery business, said, “Catalent has proven experience and expertise in drug formulation and working with partners to bring new therapies to market quickly. The Zydis technology platform has been shown to be very versatile and effective in developing easy-to-administer dose forms for innovators, and having evaluated Cycle’s molecules at our Swindon, U.K., facility, we believe them to be excellent candidates for further development.”